Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
Aim. To perform health-economic evaluation of vemurafenib in comparison to dabrafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation in Russia from the healthcare system perspective. Materials and methods. Mathematical modelling and cost effectiveness analysis with cost...
Main Authors: | A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2018-05-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/73 |
Similar Items
-
Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma
by: E. G. Kosolapov, et al.
Published: (2018-05-01) -
Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
by: Tianfu Gao, et al.
Published: (2021-06-01) -
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
by: Adil Daud, et al.
Published: (2017-01-01) -
Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi M, et al.
Published: (2016-05-01) -
Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report
by: Stefano Cavalieri, et al.
Published: (2017-07-01)